Shanghai Rendu Biotechnology Co. Ltd. A
Shanghai Rendu Biotechnology Co., Ltd. engages in the research, development, production, and sales of RNA molecular diagnostic technology and products. It offers products in the areas of reproductive health, bloodborne infections, respiratory infections, enterovirus infections, cancer early detection, and other areas; and AutoSAT, SuperSAT, and ultrasonic homogenizer. The company was founded in 2… Read more
Shanghai Rendu Biotechnology Co. Ltd. A (688193) - Total Assets
Latest total assets as of June 2025: CN¥984.94 Million CNY
Based on the latest financial reports, Shanghai Rendu Biotechnology Co. Ltd. A (688193) holds total assets worth CN¥984.94 Million CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai Rendu Biotechnology Co. Ltd. A - Total Assets Trend (2019–2024)
This chart illustrates how Shanghai Rendu Biotechnology Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shanghai Rendu Biotechnology Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Rendu Biotechnology Co. Ltd. A's total assets of CN¥984.94 Million consist of 89.0% current assets and 11.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 26.3% |
| Accounts Receivable | CN¥49.37 Million | 5.0% |
| Inventory | CN¥25.14 Million | 2.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥409.62K | 0.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Shanghai Rendu Biotechnology Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Rendu Biotechnology Co. Ltd. A's current assets represent 89.0% of total assets in 2024, an increase from 58.1% in 2019.
- Cash Position: Cash and equivalents constituted 26.3% of total assets in 2024, up from 22.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 5.0% of total assets.
Shanghai Rendu Biotechnology Co. Ltd. A Competitors by Total Assets
Key competitors of Shanghai Rendu Biotechnology Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.17 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.47 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Shanghai Rendu Biotechnology Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shanghai Rendu Biotechnology Co. Ltd. A generates 0.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Shanghai Rendu Biotechnology Co. Ltd. A is currently not profitable relative to its asset base.
Shanghai Rendu Biotechnology Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.39 | 11.93 | 9.83 |
| Quick Ratio | 13.03 | 11.58 | 9.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥814.92 Million | CN¥ 796.54 Million | CN¥ 882.42 Million |
Shanghai Rendu Biotechnology Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Shanghai Rendu Biotechnology Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.20 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -5.7% |
| Total Assets | CN¥994.36 Million |
| Market Capitalization | $127.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Rendu Biotechnology Co. Ltd. A's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Rendu Biotechnology Co. Ltd. A's assets decreased by 5.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Rendu Biotechnology Co. Ltd. A (2019–2024)
The table below shows the annual total assets of Shanghai Rendu Biotechnology Co. Ltd. A from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥994.36 Million | -5.72% |
| 2023-12-31 | CN¥1.05 Billion | -3.12% |
| 2022-12-31 | CN¥1.09 Billion | +187.56% |
| 2021-12-31 | CN¥378.61 Million | +21.82% |
| 2020-12-31 | CN¥310.79 Million | +66.14% |
| 2019-12-31 | CN¥187.07 Million | -- |